CN104203896A - 用于制备中链长度脂肪酸的三酸甘油酯的方法 - Google Patents
用于制备中链长度脂肪酸的三酸甘油酯的方法 Download PDFInfo
- Publication number
- CN104203896A CN104203896A CN201380011748.5A CN201380011748A CN104203896A CN 104203896 A CN104203896 A CN 104203896A CN 201380011748 A CN201380011748 A CN 201380011748A CN 104203896 A CN104203896 A CN 104203896A
- Authority
- CN
- China
- Prior art keywords
- triglyceride
- approximately
- lipid acid
- chain length
- medium chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 150000003626 triacylglycerols Chemical class 0.000 title claims abstract description 8
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract description 9
- 239000000194 fatty acid Substances 0.000 title abstract description 9
- 229930195729 fatty acid Natural products 0.000 title abstract description 9
- 150000004665 fatty acids Chemical class 0.000 title abstract description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 79
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000006243 chemical reaction Methods 0.000 claims abstract description 15
- 239000003054 catalyst Substances 0.000 claims abstract description 9
- 230000008569 process Effects 0.000 claims abstract description 9
- 229910052751 metal Inorganic materials 0.000 claims abstract description 8
- 239000002184 metal Substances 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000002253 acid Substances 0.000 claims description 70
- 150000002632 lipids Chemical class 0.000 claims description 69
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000243 solution Substances 0.000 claims description 47
- 235000011187 glycerol Nutrition 0.000 claims description 31
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 28
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 20
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000292 calcium oxide Substances 0.000 claims description 16
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000001816 cooling Methods 0.000 claims description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 12
- QGLKJKCYBOYXKC-UHFFFAOYSA-N nonaoxidotritungsten Chemical group O=[W]1(=O)O[W](=O)(=O)O[W](=O)(=O)O1 QGLKJKCYBOYXKC-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 229910001930 tungsten oxide Inorganic materials 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 10
- 239000011787 zinc oxide Substances 0.000 claims description 10
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 9
- 229910002027 silica gel Inorganic materials 0.000 claims description 9
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000000395 magnesium oxide Substances 0.000 claims description 6
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 6
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical group [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- 229910021555 Chromium Chloride Inorganic materials 0.000 claims description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 3
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 claims description 3
- RGXWDWUGBIJHDO-UHFFFAOYSA-N ethyl decanoate Chemical compound CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 claims description 3
- 229910000476 molybdenum oxide Inorganic materials 0.000 claims description 3
- PDKHNCYLMVRIFV-UHFFFAOYSA-H molybdenum;hexachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mo] PDKHNCYLMVRIFV-UHFFFAOYSA-H 0.000 claims description 3
- PQQKPALAQIIWST-UHFFFAOYSA-N oxomolybdenum Chemical compound [Mo]=O PQQKPALAQIIWST-UHFFFAOYSA-N 0.000 claims description 3
- YOUIDGQAIILFBW-UHFFFAOYSA-J tetrachlorotungsten Chemical compound Cl[W](Cl)(Cl)Cl YOUIDGQAIILFBW-UHFFFAOYSA-J 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- FQNHWXHRAUXLFU-UHFFFAOYSA-N carbon monoxide;tungsten Chemical group [W].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] FQNHWXHRAUXLFU-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 2
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- 235000021588 free fatty acids Nutrition 0.000 abstract description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052749 magnesium Inorganic materials 0.000 abstract description 5
- 239000011777 magnesium Substances 0.000 abstract description 5
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 abstract description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229910052750 molybdenum Inorganic materials 0.000 abstract description 4
- 239000011733 molybdenum Substances 0.000 abstract description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 abstract description 4
- 229910052721 tungsten Inorganic materials 0.000 abstract description 4
- 239000010937 tungsten Substances 0.000 abstract description 4
- 239000011701 zinc Substances 0.000 abstract description 4
- 229910052725 zinc Inorganic materials 0.000 abstract description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 abstract description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 abstract description 3
- 229910052804 chromium Inorganic materials 0.000 abstract description 3
- 239000011651 chromium Substances 0.000 abstract description 3
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 2
- 239000002243 precursor Substances 0.000 abstract description 2
- 239000002904 solvent Substances 0.000 abstract description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000002314 glycerols Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 11
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 10
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 10
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N trilaurin Chemical compound CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 7
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000032050 esterification Effects 0.000 description 6
- 238000005886 esterification reaction Methods 0.000 description 6
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000004064 recycling Methods 0.000 description 5
- 239000005639 Lauric acid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000003365 glass fiber Substances 0.000 description 3
- 125000005908 glyceryl ester group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 239000001074 1-methoxy-4-[(E)-prop-1-enyl]benzene Substances 0.000 description 1
- ZBCATMYQYDCTIZ-UHFFFAOYSA-N 4-methylcatechol Chemical compound CC1=CC=C(O)C(O)=C1 ZBCATMYQYDCTIZ-UHFFFAOYSA-N 0.000 description 1
- IREHUTXWKLKVDU-UHFFFAOYSA-N C(CCCCCCCCC)(=O)O.[C] Chemical group C(CCCCCCCCC)(=O)O.[C] IREHUTXWKLKVDU-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000013530 defoamer Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- -1 inhalation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 125000005474 octanoate group Chemical class 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 1
- MAYCICSNZYXLHB-UHFFFAOYSA-N tricaproin Chemical compound CCCCCC(=O)OCC(OC(=O)CCCCC)COC(=O)CCCCC MAYCICSNZYXLHB-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C3/00—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom
- C11C3/02—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol
- C11C3/025—Fats, oils, or fatty acids by chemical modification of fats, oils, or fatty acids obtained therefrom by esterification of fatty acids with glycerol with a stoechiometric excess of glycerol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Fats And Perfumes (AREA)
Abstract
Description
Claims (34)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261605489P | 2012-03-01 | 2012-03-01 | |
US61/605489 | 2012-03-01 | ||
PCT/CA2013/000174 WO2013126990A1 (en) | 2012-03-01 | 2013-02-28 | Method for the preparation of triglycerides of medium-chain length fatty acids |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104203896A true CN104203896A (zh) | 2014-12-10 |
CN104203896B CN104203896B (zh) | 2018-05-15 |
Family
ID=49081484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201380011748.5A Expired - Fee Related CN104203896B (zh) | 2012-03-01 | 2013-02-28 | 用于制备中链长度脂肪酸的三酸甘油酯的方法 |
Country Status (21)
Country | Link |
---|---|
US (1) | US9447016B2 (zh) |
EP (1) | EP2819989B1 (zh) |
JP (1) | JP6148690B2 (zh) |
KR (1) | KR102098974B1 (zh) |
CN (1) | CN104203896B (zh) |
AU (1) | AU2013225572B2 (zh) |
CA (1) | CA2865664C (zh) |
DK (1) | DK2819989T3 (zh) |
ES (1) | ES2719077T3 (zh) |
HK (1) | HK1205096A1 (zh) |
IL (1) | IL234104A (zh) |
MX (1) | MX355572B (zh) |
NZ (1) | NZ629227A (zh) |
PH (1) | PH12014501863A1 (zh) |
PL (1) | PL2819989T3 (zh) |
PT (1) | PT2819989T (zh) |
RU (1) | RU2641307C2 (zh) |
TR (1) | TR201905237T4 (zh) |
TW (1) | TWI572352B (zh) |
WO (1) | WO2013126990A1 (zh) |
ZA (1) | ZA201405956B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104689327A (zh) * | 2015-03-23 | 2015-06-10 | 山东北大高科华泰制药有限公司 | 谷维素液体组合物 |
CN107129430A (zh) * | 2017-05-09 | 2017-09-05 | 新兴(铁岭)药业股份有限公司 | 一种原料药中链甘油三酸酯合成方法 |
CN109836328A (zh) * | 2019-03-16 | 2019-06-04 | 广州隽沐生物科技股份有限公司 | 中链甘油三酸酯的合成方法 |
CN110105203A (zh) * | 2019-04-30 | 2019-08-09 | 沈阳化工大学 | 一种乙酰丙酸六碳酯的制备方法 |
CN110204440A (zh) * | 2019-04-30 | 2019-09-06 | 沈阳化工大学 | 一种乙酰丙酸基液体燃料的制备方法 |
CN115536531A (zh) * | 2022-11-02 | 2022-12-30 | 湖北葛店人福药用辅料有限责任公司 | 一种三辛酸甘油酯的制备方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY177028A (en) * | 2013-11-14 | 2020-09-02 | Ultragenyx Pharmaceutical Inc | Solid compositions of triglycerides and uses thereof |
PH12014000195A1 (en) | 2014-07-10 | 2017-01-23 | Lao Dean Jr | Preparation and composition of medium chain triglycerides containing substantial amount of lauric acid |
BR112017007066A2 (pt) * | 2014-10-10 | 2017-12-12 | Nestec Sa | composições e métodos para melhorar a mobilidade ou a atividade, ou tratar a debilidade |
CN117017965A (zh) | 2015-12-04 | 2023-11-10 | 雀巢产品有限公司 | 中链三甘油酯组合物 |
JP6847514B2 (ja) * | 2017-01-20 | 2021-03-24 | 日清オイリオグループ株式会社 | 固化性又は結晶性トリグリセリド |
ES2947367T3 (es) | 2017-07-26 | 2023-08-07 | Tgx Soft Chew Llc | Masticable blando sin almidón para aplicaciones veterinarias |
KR102043442B1 (ko) * | 2019-02-01 | 2019-11-11 | 주식회사 천강 | 지방산 및 유리지방산을 다량 함유한 유지를 촉매를 사용하지 않고 바이오디젤 원료용 저산가 글리세라이드를 제조하는 방법 |
FR3112344B1 (fr) | 2020-07-10 | 2022-12-23 | Arkema France | Procédé de préparation d’un triglycéride d’acide heptanoïque |
CN112321422B (zh) * | 2020-10-27 | 2023-04-25 | 湖北葛店人福药用辅料有限责任公司 | 辛酸癸酸单双甘油酯的制备方法 |
EP4313931A1 (en) * | 2021-05-21 | 2024-02-07 | IOI Oleo GmbH | Process for producing high-grade fatty acid polyol esters, particularly fatty acid glycerol esters |
WO2023076737A1 (en) * | 2021-11-01 | 2023-05-04 | Bioveritas, Llc | Triglycerides and structured lipids from short- and medium-chain fatty acids |
WO2024069590A1 (en) | 2022-09-30 | 2024-04-04 | Amyris Bio Products Portugal, Unipessoal, Ltda. | Compositions and methods for preservation of food and cosmetic products |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594274A (zh) * | 2004-07-01 | 2005-03-16 | 江南大学 | 一种中碳链甘三酯的合成和纯化方法 |
CN101381304A (zh) * | 2008-10-22 | 2009-03-11 | 上海化工研究院 | 一种甘油三辛酸酯-羧基-13c3的合成方法 |
CN101903509A (zh) * | 2007-12-19 | 2010-12-01 | 拜尔技术服务有限责任公司 | 用于制备脂肪酸烷基酯的方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB978085A (en) * | 1961-12-11 | 1964-12-16 | Canada Packers Ltd | Edible oils from tall oil fatty acids |
JPS5145105A (en) * | 1974-10-16 | 1976-04-17 | Nisshin Oil Mills Ltd | Goseiyuno seiseihoho |
JPS6256452A (ja) * | 1985-09-04 | 1987-03-12 | Nippon Oil & Fats Co Ltd | エステルの製造法 |
JPH04145046A (ja) * | 1990-10-03 | 1992-05-19 | New Japan Chem Co Ltd | ポリグリセリン脂肪酸エステルの製造方法 |
US6835750B1 (en) * | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
PL223348B1 (pl) * | 2001-04-18 | 2016-10-31 | Prometic Biosciences Inc | Zastosowanie karboksylanu |
DE10130491A1 (de) * | 2001-06-25 | 2003-04-17 | Heirler Horst | Verwendung von mittelkettigen Triglyceriden zur Prävention und Therapie von Adipositas |
JP2003135001A (ja) * | 2001-11-02 | 2003-05-13 | Nisshin Oillio Ltd | 食用油脂及びそれを用いた乳化油脂組成物 |
AP2005003367A0 (en) * | 2003-02-07 | 2005-09-30 | Prometic Biosciences Inc | Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis. |
FR2884716B1 (fr) * | 2005-04-22 | 2009-08-21 | Thea Sa Lab | Utilisation de l'azithromycine pour la fabrication d'un medicament destine au traitement des infections oculaires |
KR100737742B1 (ko) * | 2005-12-05 | 2007-07-10 | 대화제약 주식회사 | 파클리탁셀 조성물의 제조 방법 |
JP2008174483A (ja) * | 2007-01-18 | 2008-07-31 | Gifu Univ | カルボン酸多価アルコールエステルの製造方法 |
-
2013
- 2013-02-27 TW TW102106946A patent/TWI572352B/zh not_active IP Right Cessation
- 2013-02-28 ES ES13755282T patent/ES2719077T3/es active Active
- 2013-02-28 MX MX2014010446A patent/MX355572B/es active IP Right Grant
- 2013-02-28 PL PL13755282T patent/PL2819989T3/pl unknown
- 2013-02-28 WO PCT/CA2013/000174 patent/WO2013126990A1/en active Application Filing
- 2013-02-28 NZ NZ629227A patent/NZ629227A/en not_active IP Right Cessation
- 2013-02-28 PT PT13755282T patent/PT2819989T/pt unknown
- 2013-02-28 JP JP2014559042A patent/JP6148690B2/ja not_active Expired - Fee Related
- 2013-02-28 CN CN201380011748.5A patent/CN104203896B/zh not_active Expired - Fee Related
- 2013-02-28 KR KR1020147027579A patent/KR102098974B1/ko active IP Right Grant
- 2013-02-28 AU AU2013225572A patent/AU2013225572B2/en not_active Ceased
- 2013-02-28 TR TR2019/05237T patent/TR201905237T4/tr unknown
- 2013-02-28 CA CA2865664A patent/CA2865664C/en active Active
- 2013-02-28 RU RU2014139702A patent/RU2641307C2/ru active
- 2013-02-28 US US14/382,080 patent/US9447016B2/en active Active
- 2013-02-28 DK DK13755282.4T patent/DK2819989T3/en active
- 2013-02-28 EP EP13755282.4A patent/EP2819989B1/en active Active
-
2014
- 2014-08-13 IL IL234104A patent/IL234104A/en active IP Right Grant
- 2014-08-14 ZA ZA2014/05956A patent/ZA201405956B/en unknown
- 2014-08-18 PH PH12014501863A patent/PH12014501863A1/en unknown
-
2015
- 2015-06-08 HK HK15105417.7A patent/HK1205096A1/zh not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1594274A (zh) * | 2004-07-01 | 2005-03-16 | 江南大学 | 一种中碳链甘三酯的合成和纯化方法 |
CN101903509A (zh) * | 2007-12-19 | 2010-12-01 | 拜尔技术服务有限责任公司 | 用于制备脂肪酸烷基酯的方法 |
CN101381304A (zh) * | 2008-10-22 | 2009-03-11 | 上海化工研究院 | 一种甘油三辛酸酯-羧基-13c3的合成方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104689327A (zh) * | 2015-03-23 | 2015-06-10 | 山东北大高科华泰制药有限公司 | 谷维素液体组合物 |
CN104689327B (zh) * | 2015-03-23 | 2019-02-12 | 山东北大高科华泰制药有限公司 | 谷维素液体组合物 |
CN107129430A (zh) * | 2017-05-09 | 2017-09-05 | 新兴(铁岭)药业股份有限公司 | 一种原料药中链甘油三酸酯合成方法 |
CN107129430B (zh) * | 2017-05-09 | 2020-08-21 | 辽宁新兴药业股份有限公司 | 一种原料药中链甘油三酸酯合成方法 |
CN109836328A (zh) * | 2019-03-16 | 2019-06-04 | 广州隽沐生物科技股份有限公司 | 中链甘油三酸酯的合成方法 |
CN110105203A (zh) * | 2019-04-30 | 2019-08-09 | 沈阳化工大学 | 一种乙酰丙酸六碳酯的制备方法 |
CN110204440A (zh) * | 2019-04-30 | 2019-09-06 | 沈阳化工大学 | 一种乙酰丙酸基液体燃料的制备方法 |
CN115536531A (zh) * | 2022-11-02 | 2022-12-30 | 湖北葛店人福药用辅料有限责任公司 | 一种三辛酸甘油酯的制备方法 |
CN115536531B (zh) * | 2022-11-02 | 2024-05-28 | 湖北葛店人福药用辅料有限责任公司 | 一种三辛酸甘油酯的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104203896A (zh) | 用于制备中链长度脂肪酸的三酸甘油酯的方法 | |
CN101265226A (zh) | 化合物和释放前列环素类似物的方法 | |
SK279946B6 (sk) | Farmaceutická kompozícia, spôsob jej prípravy a in | |
EP2767533B1 (en) | Derivative of butylphthalide and preparation method and use thereof | |
CA3149104A1 (en) | Micromolecule pi4kiiia inhibitor composition, preparation method therefor and use thereof | |
CN101456814A (zh) | 右旋布洛芬愈创木酚酯及其制备方法 | |
WO2020181256A1 (en) | Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same | |
CN116018140A (zh) | 多奈哌齐醚棕榈酸酯或其药用盐 | |
JP2003514826A (ja) | β−D−5−チオキシロース誘導体、調製法及び治療上の使用 | |
CN112110966B (zh) | 白藜芦醇糖苷类衍生物、制备和用途 | |
JP6205009B2 (ja) | ホスホノクロトン酸誘導体の製造方法 | |
CN105884766B (zh) | 一种合成米诺磷酸中间体的方法 | |
EP4292593A1 (en) | Pharmaceutical composition for preventing cytokine storm | |
JP6265550B2 (ja) | アスコルビン酸誘導体組成物およびその製造方法、アスコルビン酸誘導体溶液、皮膚外用剤 | |
JP2002241366A (ja) | ハイドロキノン誘導体および動脈硬化治療用組成物 | |
JP2011032255A (ja) | 消臭、殺菌、除菌、滅菌および防カビ剤 | |
CN114957169A (zh) | 一种紫杉醇棕榈酸酯的制备方法 | |
JPH0667869B2 (ja) | 副腎白質ジストロフィーを治療するための医薬組成物 | |
WO2021138561A1 (en) | Novel tetrahydrocurcumin compositions, methods of making, and methods of using the same | |
OA20568A (en) | Micromolecule PI4Klllα inhibitor composition, preparation method therefor and use thereof. | |
JPH04290846A (ja) | トリテルペノイド化合物およびその用途 | |
CN115160399A (zh) | 一种皂皮酸类化合物及其制备方法和医用用途 | |
JPS6345273A (ja) | α−トコフエロ−ル誘導体 | |
JPH10168090A (ja) | アポトーシス誘導剤 | |
BE437740A (zh) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1205096 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160725 Address after: cambridge Applicant after: PROMETIC BIOSCIENCES Inc. Address before: Quebec Applicant before: Prometic Biosciences Inc. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1205096 Country of ref document: HK |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for the preparation of triglycerides of medium-chain length fatty acids Effective date of registration: 20181016 Granted publication date: 20180515 Pledgee: Structured Alfa L.P. Pledgor: PROMETIC BIOSCIENCES Inc. Registration number: 2018990000969 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180515 |
|
CF01 | Termination of patent right due to non-payment of annual fee |